{"entity":{"id":"2033","kind":"year","name":"2033 in oncology","aka":["2033"],"tldr":"Everything OnCo dates to 2033: 2 entries, 2 expected dates. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"2 dated entries in OnCo fall in 2033: 2 expected dates.\n\nOf those, 2 to the day. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2032"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2033,"events":[{"group":"expected","date":"2033-03-31","precision":"day","title":"SCARLET (S2212) primary completion: shorter anthracycline-free chemo-immunotherapy vs the KEYNOTE-522 regimen (2,400 estimated participants)","note":"Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...","from":"tnbc-roadmap","refs":["scarlet-s2212","keynote-522","anthracycline","de-escalation"]},{"group":"expected","date":"2033-05-31","precision":"day","title":"OptimICE-pCR primary completion: adjuvant pembrolizumab vs observation after pathological complete response to chemotherapy plus pembrolizumab (1,295 estimated...","note":"Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...","from":"tnbc-roadmap","refs":["optimice-pcr","pembrolizumab","pcr","de-escalation"]}]},"route":"/years/2033/","neighbours":{"year":[{"id":"2032","kind":"year","name":"2032 in oncology","route":"/years/2032/"}]}}